Back

Beta-blockers for LQT3: Contraindicated, acceptable or the drug of choice?

20 June 2017 (09:15 - 09:37)
Organised by:
Congress Presentation Part of: Medical treatment of channelopathies: effective and safe? Pharmacology EHRA Premium Access EHRA EUROPACE - CARDIOSTIM 2017

About the speaker

Photo
Professor Arthur Wilde

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

3 More presentations in this session

Presentation thumbnail
Quinidine for Brugada and what to do with Quinidine intolerance.
Professor W. Shimizu (Matsudo, JP)
Slides Video
Presentation thumbnail
Ranolazine for LQT3: s treatment that found it's disease?
Professor S. Viskin (Tel Aviv, IL)
Slides Video
Presentation thumbnail
LQT3 – the role of Ajmaline challenge and of Flecainide and mexilletine in treatment.
Professor P. Schwartz (Milan, IT)

Access the full session

Session thumbnail
Medical treatment of channelopathies: effective and safe?

The Event

Event poster

EHRA EUROPACE - CARDIOSTIM 2017

20 June 2017 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Is mexiletine ready for prime time in patients with Type 2 Long QT Syndrome?
28 August 2020
thumbnail
Congress Presentation
Discussant review - REBOOT-CNIC, BETAMI-DANBLOCK, CAPITAL-RCT
30 August 2025
thumbnail
Congress Presentation
Betablockers or calcium channel blockers in hypertrophic cardiomyopathy
22 May 2023
thumbnail
Congress Presentation
Treating the unknown: the use of anti-arrhtyhmic drugs in idiopathic ventricular fibrillation
14 April 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources